Pharmacologic Characterization Of Bms-191095, A Mitochondrial K-Atp Opener With No Peripheral Vasodilator Or Cardiac Action Potential Shortening Activity

Previous work described ATP-sensitive K+ channel (K-ATP) openers (e.g,, BMS-180448), which retain the cardioprotective activity of agents such as cromakalim while being significantly less potent as vasodilators. in this study, we describe the pharmacologic profile of BMS-191095, which is devoid of peripheral vasodilating activity while retaining glyburide-reversible cardioprotective activity. In isolated rat hearts subjected to 25 min of global ischemia and 30 min of reperfusion, BMS-191095 increased the time to onset of ischemic contracture with an EC25 of 1.5 muM, which is comparable to 4.7 muM and 3.0 muM for cromakalim and BMS-180448, respectively. Comparisons of cardioprotective and vasorelaxant potencies in vitro and in vivo showed BMS-191095 to be significantly more selective for cardioprotection with virtually no effect on peripheral smooth muscle, whereas cromakalim showed little selectivity. In addition to increasing the time to the onset of contracture, BMS-191095 improved postischemic recovery of function and reduced lactate dehydrogenase release in the isolated rat hearts. The cardioprotective effects of BMS-191095 were abolished by glyburide and sodium 5-hydroxydecanoate (5-HD). BMS-191095 did not shorten action potential duration in normal or hypoxic myocardium within its cardioprotective concentration range nor did it activate sarcolemmal K-ATP current (less than or equal to 30 muM). BMS-191095 opened cardiac mitochondrial K-ATP with a K-1/2 of 83 nM, and this was abolished by glyburide and 5-HD, These results show that the cardioprotective effects of BMS-191095 are dissociated from peripheral vasodilator and cardiac sarcolemmal K-ATP activation. Agents like BMS-191095 may owe their cardioprotective selectivity to selective mitochondrial K-ATP activation.